SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Trial Profile

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms SU2C-SARC032
  • Most Recent Events

    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 11 Jul 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
    • 21 Jun 2017 Planned End Date changed from 30 May 2025 to 30 Jul 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top